MLchartDataset catalogue

autologous 1928T2z CAR T cells WZTL-002

Term · Oncology and biomedicine · MLC-T-ONC-011314

A preparation of autologous, third-generation T lymphocytes that have been transduced with a self-inactivating lentiviral vector to express a chimeric antigen receptor (CAR) containing a single-chain variable fragment (scFv) from the monoclonal antibody FMC63, which is directed against the CD19 antigen, and linked to the co-stimulatory intracellular signaling domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta; CD28z), and the Toll/interleukin-1 receptor (TIR) domain from Toll-like receptor 2 (TLR2) as an additional co-stimulatory domain, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous 1928T2z CAR T cells WZTL-002 specifically recognize and bind to CD19-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B cells. In addition to CD28 and CD3zeta, the TLR2-TIR domain provides co-stimulatory activity and may enhance the cytotoxic effect and anti-tumor activity of the CAR T-cells. The TIR domain from TLR2 mediates the intracellular signaling of TLR2; TLR2 stimulation enhances T-cell activation, proliferation and cytokine production.

Table 1. Record
IdentifierMLC-T-ONC-011314
FieldOncology and biomedicine
SynonymsantiCD19 CAR-CD28zeta-TLR2-expressing T cells WZTL-002; autologous 1928T2z CAR-T lymphocytes WZTL-002; autologous CAR T cells WZTL-002; autologous third-generation anti-CD19 chimeric antigen receptor T cells WZTL-002
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-011314",
  "term": "autologous 1928T2z CAR T cells WZTL-002",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous, third-generation T lymphocytes that have been transduced with a self-inactivating lentiviral vector to express a chimeric antigen receptor (CAR) containing a single-chain variable fragment (scFv) from the monoclonal antibody FMC63, which is directed against the CD19 antigen, and linked to the co-stimulatory intracellular signaling domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta; CD28z), and the Toll/interleukin-1 receptor (TIR) domain from Toll-like receptor 2 (TLR2) as an additional co-stimulatory domain, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous 1928T2z CAR T cells WZTL-002 specifically recognize and bind to CD19-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B cells. In addition to CD28 and CD3zeta, the TLR2-TIR domain provides co-stimulatory activity and may enhance the cytotoxic effect and anti-tumor activity of the CAR T-cells. The TIR domain from TLR2 mediates the intracellular signaling of TLR2; TLR2 stimulation enhances T-cell activation, proliferation and cytokine production.",
  "synonyms": [
    "antiCD19 CAR-CD28zeta-TLR2-expressing T cells WZTL-002",
    "autologous 1928T2z CAR-T lymphocytes WZTL-002",
    "autologous CAR T cells WZTL-002",
    "autologous third-generation anti-CD19 chimeric antigen receptor T cells WZTL-002"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-1928t2z-car-t-cells-wztl-002/"
}

Record 2,646 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.